PEMBRO With Chemo in Neo Adj Treatment of Ovarian Cancer .
Status:
Active, not recruiting
Trial end date:
2025-03-31
Target enrollment:
Participant gender:
Summary
There are several data suggesting that pembrolizumab and bevacizumab may be synergistic.
Enhanced tumor angiogenesis is commonly associated with absence of tumor-infiltrating T cells
in patients. There is evidence in OC that tumor expression of VEGF is negatively correlated
to the density of CD3+TILs and this phenotype is associated with early recurrence, consistent
with prior studies showing a correlation of VEGF to early recurrence and short survival.
Furthermore, in ascites, high levels of VEGF correlate to low numbers of NK T-like CD3+CD56+
cells
This randomized phase II study aims to evaluate the efficacy of pembrolizumab in combina-tion
with the standard neo adjuvant chemotherapy followed by IDS and the safety of this strategy
in patients with advanced ovarian cancer. We assume that its administration in the neo
adjuvant setting combination with standard of care (4 cycles of standard chemotherapy) would
improve the response rate and consequently will help to achieve optimal debulking rate at
IDS.
After surgery, patients will continue to be treated with standard of care (chemotherapy for 2
to 5 cycles plus or less bevacizumab) or the same combination plus pembrolizumab (keytruda).